Stock Track | Impact Therapeutics-B Plummets 5.18% Intraday on Post-IPO Profit-Taking and Weak Fundamentals

Stock Track05-21

Impact Therapeutics-B's stock plummeted 5.18% during intraday trading on Thursday.

The decline reflects mounting profit-taking pressure following the company's explosive IPO debut. Impact Therapeutics listed on the Hong Kong Stock Exchange earlier this month, with its public offering oversubscribed by 2,282.4 times and surging 108.26% on the first day. Since then, the stock has retreated over 15% from its post-listing high as early investors lock in gains.

Fundamentally, the company remains in a loss-making phase, reporting a net loss of approximately RMB 296 million for 2025 on revenue of only RMB 38.25 million, insufficient to cover its intensive R&D expenditures. This limited fundamental support for its elevated valuation appears to be compounding selling pressure.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1116682247?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-21 10:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116682247","market":"sg","top_or_hot":-1,"title":"Stock Track | Impact Therapeutics-B Plummets 5.18% Intraday on Post-IPO Profit-Taking and Weak Fundamentals","media":"Stock Track","content":"<p>Impact Therapeutics-B's stock plummeted 5.18% during intraday trading on Thursday.</p><p>The decline reflects mounting profit-taking pressure following the company's explosive IPO debut. Impact Therapeutics listed on the Hong Kong Stock Exchange earlier this month, with its public offering oversubscribed by 2,282.4 times and surging 108.26% on the first day. Since then, the stock has retreated over 15% from its post-listing high as early investors lock in gains.</p><p>Fundamentally, the company remains in a loss-making phase, reporting a net loss of approximately RMB 296 million for 2025 on revenue of only RMB 38.25 million, insufficient to cover its intensive R&D expenditures. This limited fundamental support for its elevated valuation appears to be compounding selling pressure.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Impact Therapeutics-B Plummets 5.18% Intraday on Post-IPO Profit-Taking and Weak Fundamentals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Impact Therapeutics-B Plummets 5.18% Intraday on Post-IPO Profit-Taking and Weak Fundamentals\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-21 10:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Impact Therapeutics-B's stock plummeted 5.18% during intraday trading on Thursday.</p><p>The decline reflects mounting profit-taking pressure following the company's explosive IPO debut. Impact Therapeutics listed on the Hong Kong Stock Exchange earlier this month, with its public offering oversubscribed by 2,282.4 times and surging 108.26% on the first day. Since then, the stock has retreated over 15% from its post-listing high as early investors lock in gains.</p><p>Fundamentally, the company remains in a loss-making phase, reporting a net loss of approximately RMB 296 million for 2025 on revenue of only RMB 38.25 million, insufficient to cover its intensive R&D expenditures. This limited fundamental support for its elevated valuation appears to be compounding selling pressure.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"07630","symbol_name":"英派药业-B","start_time":0,"source_url":"","article_id":"1116682247","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116682247","pubTimestamp":1779330773,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Impact Therapeutics-B's stock plummeted 5.18% during intraday trading on Thursday.The decline reflects mounting profit-taking pressure following the company's explosive IPO debut. Impact Therapeutics...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"07630":"英派药业-B"},"translate_title":"个股追踪|Impact Therapeutics-B盘中暴跌5.18%受IPO后获利了结及基本面疲弱影响","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"07630":1},"content_text":"Impact Therapeutics-B's stock plummeted 5.18% during intraday trading on Thursday.The decline reflects mounting profit-taking pressure following the company's explosive IPO debut. Impact Therapeutics listed on the Hong Kong Stock Exchange earlier this month, with its public offering oversubscribed by 2,282.4 times and surging 108.26% on the first day. Since then, the stock has retreated over 15% from its post-listing high as early investors lock in gains.Fundamentally, the company remains in a loss-making phase, reporting a net loss of approximately RMB 296 million for 2025 on revenue of only RMB 38.25 million, insufficient to cover its intensive R&D expenditures. This limited fundamental support for its elevated valuation appears to be compounding selling pressure.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.4","shortVersion":"4.42.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1116682247","isCrawlerRequest":true}